Immatics N.V. $IMTX Shares Acquired by Aberdeen Group plc

Aberdeen Group plc increased its stake in shares of Immatics N.V. (NASDAQ:IMTX) by 9.7% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 789,446 shares of the company’s stock after buying an additional 69,860 shares during the quarter. Aberdeen Group plc owned about 0.65% of Immatics worth $6,726,000 at the end of the most recent quarter.

Other hedge funds also recently added to or reduced their stakes in the company. Bank of America Corp DE increased its position in Immatics by 166.0% in the 4th quarter. Bank of America Corp DE now owns 3,575 shares of the company’s stock valued at $25,000 after acquiring an additional 2,231 shares during the period. Vanguard Personalized Indexing Management LLC increased its holdings in shares of Immatics by 8.3% during the third quarter. Vanguard Personalized Indexing Management LLC now owns 47,635 shares of the company’s stock valued at $406,000 after purchasing an additional 3,666 shares during the period. Mitsubishi UFJ Asset Management Co. Ltd. raised its stake in shares of Immatics by 28.7% during the second quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 31,894 shares of the company’s stock valued at $172,000 after purchasing an additional 7,116 shares in the last quarter. Engineers Gate Manager LP acquired a new stake in Immatics in the second quarter worth about $124,000. Finally, Fox Run Management L.L.C. acquired a new position in Immatics during the 2nd quarter valued at about $136,000. 64.41% of the stock is currently owned by institutional investors.

Immatics Price Performance

Immatics stock opened at $10.06 on Friday. Immatics N.V. has a one year low of $3.30 and a one year high of $12.41. The company’s fifty day moving average price is $9.89 and its two-hundred day moving average price is $8.90. The company has a market capitalization of $1.22 billion, a price-to-earnings ratio of -9.86 and a beta of 1.36.

Wall Street Analysts Forecast Growth

IMTX has been the topic of several research analyst reports. Leerink Partners reiterated an “outperform” rating and set a $17.00 price target on shares of Immatics in a research report on Thursday, December 4th. Weiss Ratings restated a “sell (d-)” rating on shares of Immatics in a report on Thursday, January 22nd. Wall Street Zen upgraded Immatics from a “sell” rating to a “hold” rating in a report on Saturday. Mizuho set a $25.00 target price on Immatics in a research report on Thursday. Finally, Guggenheim increased their price target on Immatics from $16.00 to $19.00 and gave the company a “buy” rating in a research report on Tuesday, November 18th. Six research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, Immatics currently has an average rating of “Moderate Buy” and a consensus target price of $19.20.

Immatics Profile

Immatics N.V. (NASDAQ: IMTX) is a clinical-stage biotechnology company dedicated to the development of T cell receptor (TCR)-based immunotherapies for solid tumors. The company leverages its proprietary discovery and engineering platforms to identify tumor-specific peptide targets and develop therapies that harness the power of a patient’s immune system. Immatics’ approach aims to generate durable responses by guiding T cells to recognize and kill cancer cells with high precision.

At the core of Immatics’ technology suite is the XPRESIDENT® platform, which mines the cancer peptidome to uncover novel tumor antigens naturally presented on the surface of cancer cells.